Stock analysis, trade plans, and proprietary indicators by Trend Edge.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: April 14, 2004
Headquarters: 101 Redwood Shores Parkway, Redwood City, CA, United States, 94065
Founder-Led: Yes — Joseph K. Belanoff (Chief Executive Officer, President and Director)
Key Metrics
Current Price
$60.36
Market Cap
$6.41B
Float
89.0M
Shares Outstanding
107.4M
P/E (Forward)
74.07
P/E (TTM)
170.54
Price/Sales (TTM)
8.33
vs. Analyst Target
+30.9% to analyst PT
Profit Margin
6.16%
Operating Margin (TTM)
-30.08%
Revenue (TTM)
$769M
Earnings Growth (YoY)
-21.60%
Dividend Rate
None
Analyst Target Price
$79.00 (6 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$354M
$106M
$348M
$130M
2021
$366M
$113M
$361M
$128M
2022
$402M
$101M
$396M
$116M
2023
$482M
$106M
$476M
$108M
2024
$675M
$140M
$664M
$138M
2025
$761M
$99.7M
$748M
$46.7M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
$194M
$35.1M
Sep 2025
$208M
$19.7M
Dec 2025
$202M
$24.3M
Mar 2026
$165M
-$31.2M
Ownership & Float
Insider Ownership
11.5%
Institutional Ownership
75.7%
Short Float
12.0%
% of All Funds Holding
3.88%
Number of Funds Holding
319
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$49.49
Near-term / short-term trend
Weekly
40-Week SMA
$58.77
Medium-term trend
Weekly
80-Week SMA
$62.01
Cyclical trend (business cycle)
Weekly
200-Week SMA
$41.57
Secular trend (multi-year)
Monthly
10-Month SMA
$56.33
Near-term monthly trend
Monthly
20-Month SMA
$62.60
Medium-term monthly trend
Monthly
40-Month SMA
$45.26
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$78.00
resistance
1.60x
4 months ago
$114.00
resistance
1.76x
12 months ago
$23.10
support
1.19x
23 months ago
Historical Earnings Reactions (89 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.48%
0.00%
48.31%
26.68%
-14.16%
1 Day
0.33%
-0.21%
47.19%
24.91%
-14.29%
1 Week
1.31%
1.52%
52.81%
77.78%
-47.20%
2 Weeks
1.59%
2.52%
57.30%
70.00%
-63.94%
1 Month
6.88%
5.53%
62.50%
80.24%
-64.79%
Next earnings: July 19, 2026 (53 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
2.1%
50.0%
22
Feb
0.8%
40.9%
22
Mar
14.0%
77.3%
22
Apr
0.6%
54.5%
22
May
0.4%
50.0%
22
Jun
4.4%
45.5%
22
Jul
-0.5%
45.5%
22
Aug
-0.7%
40.9%
22
Sep
6.3%
45.5%
22
Oct
-0.7%
50.0%
22
Nov
1.9%
50.0%
22
Dec
3.0%
40.9%
22
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.27%
49.2%
1041
Tuesday
0.17%
47.7%
1142
Wednesday
0.20%
49.7%
1142
Thursday
0.15%
48.3%
1121
Friday
-0.09%
47.6%
1116
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 75.7%
Insider Transactions — Smart Summary
Total insider ownership: 11.5%
Founder-led management: Joseph K. Belanoff (Chief Executive Officer, President and Director)
12-Month Insider Activity Summary
Total Filings
50
Net Value
-$44.6M
Net Shares Change
-214,762
% of Float
-0.2%
C-Suite Filings
44
Clusters Detected
8
Key Insiders
Name
Title
Net Value
Filings
Activity
Maduck Sean
President, Corcept Endocrinology
The power of attorney under which this form was signed is on file with the Commission.
-$3.8M
2
N/A
BELANOFF JOSEPH K
Chief Executive Officer
-$3.3M
2
N/A
BAKER G LEONARD JR
+$3.3M
1
1 buy
Guyer William
Chief Development Officer
-$728,140.5
2
2 sell
Robb Gary Charles
Chief Business Officer
-$562,085.05
2
2 sell
Lyon Joseph Douglas
Chief Accounting and Technology Officer
-$354,029.38
1
N/A
Transaction Clusters
Period
Filings
Insiders
Net Value
Seniority
2025-06-04 – 2025-06-18
6
6
-$6.6M
5 C-suite
2025-07-03 – 2025-07-14
4
4
-$150,602.471
3 C-suite
2025-07-21 – 2025-07-21
4
4
-$870,053.422
4 C-suite
2025-08-05 – 2025-08-12
6
5
-$7.1M
5 C-suite
2025-08-26 – 2025-09-04
5
5
-$5.8M
5 C-suite
2025-10-03 – 2025-10-15
5
5
-$6.8M
4 C-suite
2025-11-05 – 2025-11-07
4
4
-$5.7M
4 C-suite
2025-11-26 – 2025-12-03
6
4
-$6.9M
6 C-suite
Significant Filings
Date
Insider
Title
Net Value
Price After
2026-03-19
BAKER G LEONARD JR
+$3.3M
Transaction at $33.14, now +82.1%
2025-12-03
Guyer William
Chief Development Officer
-$364,070.25
Transaction at $80.90, now -25.4%
2025-06-18
Robb Gary Charles
Chief Business Officer
-$225,402.45
Transaction at $70.77, now -14.7%
2025-11-26
Guyer William
Chief Development Officer
-$364,070.25
Transaction at $80.90, now -25.4%
2025-08-26
Robb Gary Charles
Chief Business Officer
-$336,682.6
Transaction at $48.77, now +23.8%
2025-08-05
Maduck Sean
President, Corcept Endocrinology
The power of attorney under which this form was signed is on file with the Commission.
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Corcept Therapeutics Incorporated
(CORT) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.